Interpace Biosciences, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas W. Burnell
- Full Time Employees
- 111
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Morris Corporate Center 1 Parsippany NJ United States of America 07054
- IPO Date
- May 20, 1998
- CIK
- 0001054102
- Website
- interpace.com
- Similar Companies
- Business
- Interpace Biosciences, Inc. (IDXG) develops and commercializes molecular diagnostic tests and provides pathology services focused on cancer risk assessment, particularly for thyroid, pancreatic, and lung cancers. The company offers ThyGeNEXT, a next-generation sequencing-based oncogenic mutation panel that identifies mutations in indeterminate thyroid nodules highly indicative of malignancy; ThyraMIR v2, a proprietary microRNA gene expression classifier that assesses thyroid nodule malignancy risk in conjunction with ThyGeNEXT; PancraGEN, a genomic test utilizing the PathFinderTG platform for diagnosing pancreaticobiliary cancers from cysts and solid lesions; PanDNA, a molecular-only variant of PancraGEN; and RespriDx, a genomic assay distinguishing primary from metastatic or recurrent lung cancer; through its subsidiary Interpace Diagnostics LLC. Interpace Biosciences serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals primarily in the United States with international reach. Founded in 1986 and headquartered in Parsippany, New Jersey, the company changed its name from Interpace Diagnostics Group, Inc. in November 2019 following the acquisition of Cancer Genetics Inc.'s biopharma services division, which was subsequently sold as Interpace Pharma Solutions to Flagship Biosciences in August 2022. Recent developments include the full repayment of its term loan facility with BroadOak Capital in December 2025 to strengthen its balance sheet; discontinuation of PancraGEN specimen acceptance effective May 2, 2025, as part of portfolio restructuring while maintaining the test temporarily; presentation of two new posters at the 2025 American Thyroid Association Annual Meeting in September 2025 advancing thyroid diagnostics; capital restructuring of preferred stock in October 2024 aimed at pursuing a Nasdaq uplisting; and record third-quarter 2024 financial results reported in November 2024.
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
Head to Head Contrast: Retractable Technologies (NYSE:RVP) & Interpace Biosciences (OTCMKTS:IDXG)
Head to Head Analysis: Dynatronics (NASDAQ:DYNT) versus Interpace Biosciences (OTCMKTS:IDXG)
Interpace Biosciences (OTCMKTS:IDXG) Stock Crosses Above 200-Day Moving Average – Here’s What Happened
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
Interpace Biosciences Earnings Drop
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan
Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results
Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results